Investigational drug · Phase 2
NT-0796
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity and Type 2 Diabetes, Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "NT-0796"
First trial start
2025
May 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NT-0796", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity and Type 2 Diabetes
- Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NT-0796" as an intervention, largest first.
- Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusPivotal-lookingCompleted
NodThera Ltd. (a Rezera company)Industry
NCT07055516 · 176 participants · Start May 8, 2025 · Primary completion May 27, 2026
Drug: NT-0796; Placebo · For: Obesity and Type 2 Diabetes
Sites: Mesa, Arizona; Los Angeles, California; Cooper City, Florida · 11 sites in all
NodThera Ltd. (a Rezera company)Industry
NCT07220629 · 82 participants · Start Oct 2, 2025 · Primary completion Aug 21, 2026
Drug: NT-0796; Placebo · For: Obesity
Sites: Mesa, Arizona; Hialeah, Florida; Jacksonville, Florida · 9 sites in all
NodThera Ltd. (a Rezera company)Industry
NCT06129409 · 67 participants · Start Oct 10, 2023 · Primary completion Apr 15, 2024
Drug: NT-0796 · For: Cardiovascular Diseases
Sites: Miami, Florida; Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk.
Ray KK, Clarke N, Thornton P, et al. · J Am Coll Cardiol 2026
- The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.
Fawzy MN · Inflammopharmacology 2026
- Direct NLRP3 inflammasome inhibitors for cardiovascular therapeutics: a comparative review of synthetic and natural candidates.
Zhen D, Liu C, Sun X, et al. · Front Pharmacol 2026
- Ester Prodrug NLRP3 Inflammasome Inhibitor NT-0796 is Brain Active due to Activation by Local Expression of Carboxylesterase-1.
Digby Z, Diamond C, Wescott H, et al. · ACS Chem Neurosci 2026
- Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
Clarke N, Thornton P, Reader V, et al. · Mov Disord 2025
- The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model.
Thornton P, Reader V, Digby Z, et al. · Obesity (Silver Spring) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.